Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Medically eligible women who do not use HAART: the importance of abuse, drug use, and race.

Cohen MH, Cook JA, Grey D, Young M, Hanau LH, Tien P, Levine AM, Wilson TE.

Am J Public Health. 2004 Jul;94(7):1147-51.

2.

Multi-dimensional risk factor patterns associated with non-use of highly active antiretroviral therapy among human immunodeficiency virus-infected women.

Jones AS, Lillie-Blanton M, Stone VE, Ip EH, Zhang Q, Wilson TE, Cohen MH, Golub ET, Hessol NA.

Womens Health Issues. 2010 Sep;20(5):335-42. doi: 10.1016/j.whi.2010.03.005. Epub 2010 Jun 25.

3.

Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.

Dale S, Cohen M, Weber K, Cruise R, Kelso G, Brody L.

AIDS Patient Care STDS. 2014 Mar;28(3):136-43. doi: 10.1089/apc.2013.0329. Epub 2014 Feb 25.

4.

Changes in sexual behavior among HIV-infected women after initiation of HAART.

Wilson TE, Gore ME, Greenblatt R, Cohen M, Minkoff H, Silver S, Robison E, Levine A, Gange SJ.

Am J Public Health. 2004 Jul;94(7):1141-6.

5.

Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005.

Lillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, Hessol NA, Wilson TE.

Am J Public Health. 2010 Aug;100(8):1493-9. doi: 10.2105/AJPH.2008.158949. Epub 2009 Nov 12.

6.

Child sexual abuse, HIV sexual risk, and gender relations of African-American women.

Wingood GM, DiClemente RJ.

Am J Prev Med. 1997 Sep-Oct;13(5):380-4.

PMID:
9315271
7.

Self-reported childhood sexual and physical abuse and adult HIV-risk behaviors and heavy drinking.

Bensley LS, Van Eenwyk J, Simmons KW.

Am J Prev Med. 2000 Feb;18(2):151-8.

PMID:
10698246
8.

Condom use with primary partners among injecting drug users in Bangkok, Thailand and New York City, United States.

Vanichseni S, Des Jarlais DC, Choopanya K, Friedmann P, Wenston J, Sonchai W, Sotheran JL, Raktham S, Carballo M, Friedman SR.

AIDS. 1993 Jun;7(6):887-91.

PMID:
8363764
9.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
10.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
11.

Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users.

Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y; MANIF 2000 Study Group.

J Epidemiol Community Health. 2002 May;56(5):349-53.

12.

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103.

PMID:
15608532
13.

Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study.

Telzak EE, Hershow R, Kalish LA, Hardy WD Jr, Zuckerman E, Levine A, Delapenha R, DeHovitz J, Greenblatt RM, Anastos K.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):513-8.

PMID:
9859966
14.

The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS).

Navazesh M, Mulligan R, Pogoda J, Greenspan D, Alves M, Phelan J, Greenspan J, Slots J.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Dec;100(6):701-8. Epub 2005 Jan 25.

PMID:
16301151
15.

Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.

Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L.

Trop Med Int Health. 2010 Jul;15(7):825-32. doi: 10.1111/j.1365-3156.2010.02538.x. Epub 2010 May 18.

16.

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.

Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5. doi: 10.1097/QAI.0b013e31815d2f59.

PMID:
18223361
17.
18.

Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study.

Kirstein LM, Greenblatt RM, Anastos K, Levine A, French AL, Minkoff H, Silver S, Gange SJ; Women's Interagency HIV Study Collaborative Research Group.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):495-503.

PMID:
11981366
19.

Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users.

Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F.

HIV Med. 2003 Jan;4(1):33-7.

20.

Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, Telenti A, Vernazza PL, Bernasconi E, Sudre P.

J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):114-9.

PMID:
10360802

Supplemental Content

Support Center